#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    B-cell lymphoma recurrent Hereditary haemorrhagic telangiectasia Dementia Allogenic stem cell transplantation Hepatoblastoma Intracranial calcification Guillain-Barre syndrome Necrotising enterocolitis neonatal Malignant glioma Ependymoma Angelman's syndrome Stiff person syndrome Hypochondroplasia Microvillous inclusion disease Extranodal marginal zone B-cell lymphoma (MALT type) More trials…

    Learn about Rare Diseases

    Erdheim-Chester disease – Life with Disease Congenital generalised lipodystrophy – Treatment Congenital hypotransferrinaemia – Treatment Brain stem glioma – Basic Information Alveolar rhabdomyosarcoma – Treatment Mucopolysaccharidosis III Primary hyperoxaluria – Basic Information Malignant fibrous histiocytoma – Basic Information Thrombotic thrombocytopenic purpura Proteus syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Riboflavin Sodium Phosphate Fluoxetine Hydrochloride Vib1116 Valoctocogene Roxaparvovec Protrans 64Cu-Dota-Ae105 D5-Ethyl-Beta-D-Glucuronide Histidine Iph5201 Regn7075 ULIXERTINIB Basiliximab Festuca Rubra Pollen Cariprazine Caraway Oil Ngm707 Vatiquinone Metoclopramide Sumatriptan Succinate Bulevirtide More therapies…

    Learn about Your Condition

    Basal cell naevus syndrome Hypervolaemia Thrombocytopenia Thalassaemia Bronchiectasis Breast proliferative changes Polycystic ovarian syndrome Neurodegenerative disorder Malformation venous Bronchiolitis Acute hepatic failure Restless legs syndrome Myocardial ischaemia Nocturia Pharyngeal cancer stage I More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Prostate cancer

  • Study of Fuzuloparib, Abiraterone Acetate, and Prednisone for First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    • Hormone-refractory prostate cancer
    • Prostate cancer
    Investigated Drugs:
    • 4-((3-((5,6-Dihydro-2-(Trifluoromethyl)(1,2,4)Triazolo(1,5-A)Pyrazin-7(8H)-Yl)Carbonyl)-4-Fluorophenyl)Methyl)-1(2H)-Phthalazinone
    • Abiraterone Acetate
    • Prednisone
    Belgium Czechia France Hungary Poland Spain

  • Study on the Safety of Lutetium (177Lu) Zadavotide Guraxetan and Radium Ra 223 Dichloride for Patients with Bone-Metastatic Prostate Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Prostate cancer recurrent
    • Prostate cancer
    Investigated Drugs:
    • Lutetium (177Lu) Zadavotide Guraxetan
    • Radium Ra 223 Dichloride
    The Netherlands

  • Evaluation of PSMA PET/CT Imaging for Lymph Node Assessment in Patients with Intermediate and High-Risk Non-Metastatic Prostate Cancer Before Surgery

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • 2-[[5-[3-[[6-[[(5S)-5-Carboxy-5-[[(1S)-1,3-Dicarboxypropyl]Carbamoylamino]Pentyl]Amino]-6-Oxohexyl]Amino]-3-Oxopropyl]-2-Oxidophenyl]Methyl-[2-[[5-(2-Carboxyethyl)-2-Oxidophenyl]Methyl-(Carboxylatomethyl)Amino]Ethyl]Amino]Acetate:gallium-68(3+) Hydron
    • Gozetotide
    France

  • Study on Enzalutamide and Leuprorelin Acetate for Men with High-Risk Nonmetastatic Prostate Cancer After Treatment

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Enzalutamide
    • Leuprorelin Acetate
    Austria Denmark Finland France Italy The Netherlands +4

  • Study on the Effect of Adding Leuprorelin Acetate to Radiotherapy for Patients with Oligo-recurrent Prostate Cancer with Up to 4 Metastases

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Leuprorelin Acetate
    The Netherlands

  • Study on Darolutamide with Standard Therapy for Patients with High-Risk Localized Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Darolutamide
    Ireland
Previous Page
1 … 9 10 11 12 13 … 17
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!